T. Rowe Price Health Sciences Fund (PRHSX)

74.70
Net Asset Value
+0.16%
1 Day
+6.18%
Year-to-Date
Overall Morningstar Rating
Health
Style or Category
No Load
Sales Expenses
0.77%
Expense Ratio
Average
Morningstar Risk Rating™
Investment Objective The investment seeks long-term capital appreciation. The fund will normally invest at least 80% of its net assets (including any borrowings for investment purposes) in the common stocks of companies engaged in the research- development- production- or distribution of products or services related to health care- medicine- or the life sciences (collectively termed "health sciences"). While the fund can invest in companies of any size- the majority of fund assets are expected to be invested in large- and mid-capitalization companies.

Performance

1 month+4.90% 3 years+5.05%
3 months+1.38% 5 years+17.65%
1 year+18.65% Since inception+14.49%
Data through --

Peer Comparisonvs. Health

 PRHSXCategory
Performance 5-yr return+17.65%+14.29%
Expense ratio0.77%1.29%
Risk 5 year sharpe ratio1.080.89
Net assets$11.7B$2.9B
Average market cap$24.8B$9.8B
Average P/E26.722.0
Portfolio turnover38%38%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyT. Rowe Price
Fund manager & tenureZiad Bakri / 2 Years
Minimal initial investment$2,500.00
Minimum IRA investment$1,000.00

Holdings

U.S. stock93.77%
International stock5.30%
Cash0.56%
Other0.37%
Fixed income0.00%
Top 5 Sectors
Portfolio weighting
Healthcare 93.76%
Industrial materials 0.91%
Consumer service 0.89%
Financial service 0.38%
Telecommunication 0.19%
Top 10 Holdings
Portfolio weighting
UNH UnitedHealth7.02%
BDX Becton Dickinson and Co4.78%
ISRG Intuitive Surgical4.58%
VRTX Vertex Pharmaceuticals Inc3.64%
SAGE SAGE Therapeutics Inc2.64%
SYK Stryker Corp2.62%
ANTM WellPoint2.56%
TMO Thermo Fisher Scientific Inc2.33%
A Agilent Technologies Inc2.31%
CI Cigna Corp2.15%